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S. aureus represents a critical cofactor in atopic dermatitis (AD). In this paper, the prevalence of S. aureus infection/colonization
was evaluated in 117 children as well as in their cohabitants, in order to assess the value of S. aureus characterization in
predicting disease onset and severity and in providing indications for prophylaxis. Results showed that children with AD as well
as their cohabitants had a signiﬁcantly greater incidence of S. aureus infection/colonization as compared to controls. The genetic
characterization showed a virtual identity of the bacteria strains collected at diﬀerent sites of the patients with those found in the
cohabitants, suggesting both a direct transmission between the nasal reservoir and the lesions in the same atopic subject and a risk
for reinfection within family cohabitants. These data stress the need of preliminary laboratory assessment and posttherapy control
in both AD patients and their close contacts for eﬀective S. aureus eradication.
1.Introduction
Atopic dermatitis (AD) is an inﬂammatory disease aﬀecting
the skin and characterized by impaired epidermal barrier
function and cutaneous inﬂammation [1, 2]. It is clinically
characterized by an early onset, mostly occurring before 5
yearsofage[3].TheprevalenceofADhasincreasedinindus-
trialized countries during the past three decades, and among
Italianschoolchildrentheestimatedprevalenceispresentlyof
about 5.8% [4]. The eczematous skin of the patients is highly
susceptible to bacterial colonization, and Staphylococcus
aureus (S. aureus) represents the most frequent isolate [5–
8]. S. aureus is a Gram-positive opportunistic bacterium
that, although part of the normal ﬂora of the skin, can
give rise, as a consequence of clonal evolution, to virulent
strains characterized by the expression of virulence factors
and the acquisition of resistance to a number of diﬀerent
drugs including β-lactams [9]. S. aureus infection appears to
play an important role in the pathogenesis of AD by either
causing or exacerbating skin inﬂammation [10–13]. In fact,
S. aureus toxins have potent superantigenic properties (e.g.,
staphylococcal enterotoxin SEA, SEB, SEC, SED, and toxic
shocksyndrometoxin(TSST-1))andmayinducemonocytes
and lymphocytes activation, which in turn are induced to
produceseveralinﬂammatorycytokines[14,15].Inahealthy
skin, this process causes an inﬂammatory reaction with a
clinical outcome similar to that seen in AD [10].
Although the impact of S. aureus infection in the clinical
manifestation of AD is still debated, antibiotic-corticosteroid
combination therapy against S. aureus represents an impor-
tant component of the therapeutic approach to AD [16]a n d
appears eﬀective against both the occurrence of secondary2 Clinical and Developmental Immunology
infections and the severity of the disease [17]. However, it
should be also considered that the clinical beneﬁts appear
often transient and that the onset of an antibiotic resistance
represents a serious emerging problem in long-term therapy
[18, 19] suggesting the need of an accurate microbiological
analysis for a most adequate and eﬀective therapy.
In this study, we investigated the prevalence and rela-
tionship between S. aureus infection/colonization, in both
skin lesions and anterior nares, and the clinical severity
of the disease in children with AD as compared to a
control group of asymptomatic children and examined the
inﬂuence of S. aureus colonization in the family members as
a potential source for reinfection. The results indicated that
children with AD had a signiﬁcantly greater prevalence of S.
aureus infection/colonization as compared to controls. The
genetic characterization conﬁrmed the identity of bacteria
strains collected from the patients with those found in the
cohabitants, suggesting both a direct transmission between
the lesions in the same atopic subject and a risk for rein-
fection within family cohabitants. These results emphasize
the importance of a preliminary laboratory assessment and
posttherapy control in both AD patients and their close
contacts for eﬀective S. aureus eradication.
2. Patientsand Methods
2.1. Patients and Controls. Patients incoming the Pediatric
OutpatientClinicattheSanGallicanoDermatologyInstitute
were examined during a two-year period (2007-2008). One
hundred and seventeen children aged between 3 months
and 12 years (42 patients were under 12 months of age) of
both sexes, suﬀering from mild to severe AD, were included
in the study. Diagnosis of AD was based on the criteria
described by Haniﬁn and Rajka [20] .T h es e v e r i t yo fA Dw a s
measured by the scoring atopic dermatitis index (SCORAD)
of the European Task Force on atopic dermatitis. Brieﬂy, a
numeric score (1–10) was assigned to (a) extent and (b)
intensity of skin lesions and (c) to subjective symptoms like
pruritus and sleep loss. The ﬁnal SCORAD was calculated
by the following equation: a/5 + 7b/2 + c. In the present
study, the clinical expression of disease was classiﬁed as
low, medium, or high according to SCORAD values ranging
between 0 and 15, 15, and 40 or >40, respectively. Patients
did not receive any steroid or antibiotic therapy in the last
twomonthsbeforetheinitiationofthepresentstudy.Parents
andcohabitantfamilymembersofADchildrenwereaskedto
voluntarily participate to the study by allowing skin and nose
sampling and examination aimed at S. aureus isolation and
characterization.Onehundredandtensubjectsof37families
accepted to enter the study. S. aureus strains were also
examined in asymptomatic carriers consisting of 90 healthy
children, of both sexes (39/51 M/F), aged between 3 months
and 12 years and 80 adults, of both sexes, aged between
25 and 50, attending the Outpatient Dermatology Clinic
to control pigmented lesions. All samples were obtained
by sterile swabs, from skin and nose. All patients parents
and healthy volunteers gave their written informed consent
before study initiation.
2.2. Microbiological Analysis. S w a b sw e r ec o l l e c t e df r o m
lesions, normal skin areas as well as from nares of atopic
children. Nasal swabs were performed in their cohabitants
or control subjects. Samples were plated on enriched (blood
agar), selective (Mannitol Salt Agar) and diﬀerential (MRSA
ChromID-BioM´ erieux,France)mediaandincubatedfor24–
48h at 37◦C. Identiﬁcation and antimicrobial susceptibility
of S. aureus were performed by an automated diagnostic
system (Card AST P580, Vitek 2, BioM´ erieux, France) and
included the most frequently used drugs for therapeutic
use against S. aureus. Bacteria isolates were classiﬁed as
Methicillin-resistant Staphylococcus aureus (MRSA) on the
basis of resistance to oxacillin (≥4μg/mL) and positivity of
thePenicillin-BindingProteinlatexagglutinationtest(PBP2’,
Oxoid, UK).
2.3. Molecular Characterization. Molecular analysis was per-
formed through Multiplex-PCR as previously described [21]
in order to assess the expression of the following genes:
capsular antigen (cap 5-cap 8); agr-group (agr); adhesins
(hls-spa-ica A-atl-cna-sdr E-sdr C-fnb A-clf A/B); toxins
(eta-sea-sej-sec-sed-sek-seq-tst-splB-lukE); Panton-Valentine
leukocydin-PVL(lukS/F).Bioﬁlmproductionwasassessedas
previously described [22–24].
2.4. Immunoassay. To detect the production of staphylo-
coccal enterotoxins AD and toxic shock syndrome toxin-
1 (TSST-1) isolates were incubated in tryptone soya broth
and brain heart infusion, respectively, for 24h at 37◦C.
Supernatantsweretestedforthepresenceofexotoxinsbytwo
speciﬁc reverse passive latex agglutination commercial kits
(SET-RPLA and TST-RPLA) according to the instructions
of the manufacturer (Oxoid, UK). The sensitivity of these
agglutination assays is 0.5ng/mL (SET-RPLA) and 2ng/mL
(TST-RPLA), respectively.
2.5. PFGE Analysis. Genotyping of isolated S. aureus strains
was performed by pulsed-ﬁeld gel electrophoresis (PFGE)
after DNA digestion with SmaI (Fermentas ER0661), follow-
ing the CDC (Center of Disease Control and Prevention,
USA) protocol [25]. Brieﬂy, electrophoresis was performed
with pulses ranging from 5 to 45 seconds at a voltage of
6V/cm at 14◦C for 23 hours using the PFGE instrument
CHEF DR II (Bio-Rad, USA). The gels were stained for
20 minutes with ethidium bromide solution and observed
under UV illumination.
3.StatisticalAnalysis
The statistical treatment of the results gathered from the
diﬀerent groups of subjects as well as the diﬀerent clinical
outcomes was performed by applying contingency tables and
Fisher’s t test (between two groups) or χ2 test (among three
groups). The analysis has been performed by the GraphPad
Prism version 5.00 for Windows (GraphPad Software, San
Diego, Calif, USA).Clinical and Developmental Immunology 3
Table 1: Prevalence of S. aureus colonization in patients, family members, and controls. Contingency analysis and Fisher’s exact test: ∗P<
0.0001; ∗∗P = 0.0036.
Subjects Pos/all Lesional skin and nares Nares Uninvolved skin
Atopic children 66/117∗ (57%) 47/117 (40.2%) 19/117 (16.2%) 4/117 (3.4%)
Healthy children 18/90 (20%) — 18/90 0/90
Parents/relatives 31/85∗∗ (36.4%) — 31/85 0/85
Healthy adults 16/80 (20%) — 16/80 0/80
Table 2: Prevalence of S. aureus isolates in children with AD ac-
cording to age.
Age (yrs) Pos/neg (n) Positive (%)
<3 27/22 54.1
3–6 13/21 38.2
6–12 26/8 75.7
∗Chi-square test P = 0.0062.
Table 3: Prevalence of S. aureus isolates in children with AD ac-
cording to disease severity.
Disease score Pos/neg Positive (%)
Low 3/17 15.0
Medium 25/23 52.0
High 38/11 77.5
∗Chi-square test P = 0.0001
Table 4: Prevalence of S. aureus toxigenic strains in atopic and
healthy children.
Toxigenic strains
Pos/all (%)
MRSA
Positive (%)
AD lesional skin (47) 37 (79%) 6 (12.8)
AD uninvolved skin (4) 3 (75%)
AD nares (66) 51 (77%) 3 (4.5)
CTRLs nares (18) 5 (28%)∗ 0/18
∗Chi-square test ∗P<0.0001
4. Results
Of the 117 patients analyzed, 66 (57%) were found to harbor
S. aureus (Table 1). In particular, we had positive isolation
from skin lesions and nasal swabs in 47 patients (40.1%),
while 19 patients (16.2%) had only nasal S. aureus coloniza-
tion (Table 1). A prevalence of 36.4% of positive isolation
were obtained from 31 family members of 20 patients,
signiﬁcantly higher (P = 0.0036) than the nonatopic adults
examined as controls (Table 1). In healthy children, S. aureus
was isolated at a signiﬁcantly lower frequency (18 positive
out of 90, 20%, P<0.0001) from nasal swabs. Conversely,
the frequency of detection from specimens collected from
normal skin areas in patients with AD was low (4/117) and
did not signiﬁcantly diﬀer from that of healthy children
(0/90). Considering the age, the rate of positive isolation
(including either skin or nares) was signiﬁcantly higher in
the group of children aged more than six (P = 0.0062)
(Table 2). Regarding the impact on disease severity, the
presence of S. aureus colonization appeared signiﬁcantly
related to a more severe clinical expression of pediatric AD
(P = 0.0001) (Table 3).
Taking into consideration the expression of virulence
factors by S. aureus isolates, the prevalence of MRSA strains
among the total number of individual isolates in atopic
patients was 7.9%, being present in the nose (4.5%) and,
more frequently, in the skin lesion (12.8%). According to
the molecular analysis, S. aureus strains isolated from atopic
children (a total of 119, of which 96 were from skin lesion
andnaresofthesamepatients,19fromnaresofskinnegative
patients and 4 from healthy skin areas of 4 skin and nare
positive patients), 94 (79%) had one or more genes coding
for virulence factors such as adhesins, enterotoxins, TSST-1,
CAP 5/8, the PV leukocydin, or the capacity to form bioﬁlm
(Table 4). Signiﬁcant associations were found between the
severity of the disease and high bioﬁlm producing strains
or TSST-1 positivity (P = 0.0003 and P = 0.002, resp.)
(Table 5).
To evaluate the possible transmission between nares
and skin of the same patient or between patients and
their cohabitants, the genetic characterization of strains was
assessed by DNA restriction fragmentation by PFGE. Similar
PFGE patterns were exhibited by strains collected from skin
or nares in the same patient in all 47 positive cases, as
reported in Figure 1. The PFGE analysis also showed a close
similarity among patients and their cohabitants in 75% of
cases. Interestingly, a striking correspondence was found
between strains isolated from mothers and atopic children
(72%), while fathers and brothers showed a lower extent of
identity (53% and 58%, resp.). The data from DNA analysis
were conﬁrmed by bacterial phenotyping according to the
proﬁle of toxins released in the supernatants of S. aureus
cultures as detected by the immunoassay (Table 6). The data
showed a correlation between the individual patient and at
least one of the family members. Considering the expression
of drug resistance, the results indicated that strains isolated
from parents had a more complex proﬁle of drug resistance
thanthesimilarstrainsisolatedfromtheirchildren(Table 6).
5. Discussion
Although the etiology of atopic eczema remains unknown,
evidence suggests that both genetic and environmental
factors play a role in determining both the susceptibility and
the severity of the disease [5, 26]. Recent evidence suggests
that S. aureus may play a key role in the pathogenesis of
AD [8]. In fact, while S. aureus is rarely found on the skin4 Clinical and Developmental Immunology
Table 5: Molecular characterization of bacterial virulence factors of S. aureus strains isolated in children with AD and disease severity.
Disease Score Bioﬁlm Adhesins Enterotoxins PVL TSST-1 CAP 5/8
Low/High Pos/Neg Pos/Neg Pos/Neg Pos/Neg Pos/Neg
Low/Medium 19/15 32/0 26/6 1/31 12/20 34/0
High 8/43 58/0 45/13 1/57 28/31 51/0
Fisher’s t test P = 0.0003 P = 0.63 P = 0.18 P = 0.002
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Figure 1: Pulse ﬁeld gel electrophoresis (PFGE) of diﬀerent isolates
of S. aureus; the ﬁrst and last lanes correspond to the DNA ladder;
lanes1–4correspondtostrainscollectedfromlesionalskin(1),nose
(2), healthy skin (3) of an atopic patient (patient 16), and his father
(4);lanes7–12showsimilarstrainsisolatedfromlesionalskin,nose,
healthy skin of an atopic patient (patient 26) and related mother,
father, and brother.
of healthy subjects, as conﬁrmed by our data on 80 control
children, is very frequently found in patients suﬀering of
atopic eczema. Several possible pathogenic mechanisms have
beensuggestedfortheroleofS.aureusinfection/colonization
in AD pathogenesis pointing at either a direct chemical
irritation or a nonspeciﬁc reaction of the S. aureus protein
A with immune cells [27] as well as possible mechanisms
involving superantigens production [28], which, in turn,
exacerbates or maintain skin inﬂammation in atopic eczema.
Indeed, S. aureus produces a group of toxins, which are
capable of stimulating large populations of T-lymphocytes,
even at distance from the eczematous sites, thus sustaining
the activation of the immune system and the persistence of
existing lesions. Conversely, the use of oral antibiotics as well
as of topical antibiotics/antiseptics in combination with a
topical steroid, antifungal agents or antiseptic bath additives,
are often eﬀective for the clinical management of AD and
help reduce the severity of eczema and at improving the
quality of life.
In the present study, we characterized the strains of
S. aureus isolated from skin lesion and anterior nares of
children with atopic dermatitis and from their cohabitants.
The same analysis was performed in healthy subjects either
children or adults. Our ﬁndings showed that the incidence
of S. aureus infection/colonization is higher in children
with AD, as compared to matched healthy controls (P<
0.0001) (Table 1). These data are in agreement with the
prevalence previously found by others (50%−64.2%) [29,
30]. Interestingly, the prevalence of S. aureus colonization
was higher in the patient’s relatives (36%) (P = 0.0036)
than that found in adult healthy subjects (Table 1). In fact,
S. aureus isolates obtained from diﬀerent sites of the same
patients had a close biologic and molecular identity with
those collected from patients’ cohabitants (P<0.0001),
indicating that they harbored the same S. aureus strain. A
reason for such a high rate of S. aureus colonization among
the cohabitants of pediatric patients should be probably due
to the close physical contact occurring between children and
parents/relatives, especially required for care giving. This
may concur in establishing a source for reinfection among
family members as well as other cohabitants and may sustain
intrafamiliar spreading with persistence or reactivation of
the disease [30–32]. Considering the expression of drug
resistance, results showed in Table 6 indicated that strains
isolated from parents had a more complex proﬁle of drug
resistance than the similar strains isolated from their chil-
dren. This could be probably due to an increased exposure
to antibiotics given both systemically and locally in adults
during their lives. On the other hand, we also found that
the presence of S. aureus was associated with an age under
three yrs or more than six yrs (P = 0.0062) (Table 2), and
with a more marked severity of the disease (Table 3). It
could be hypothesized that the exposure during the neonatal
period is due to the close contact with their caregivers, while
older children more frequently interact with the external
environment. The assessment of the bacterial genotypic and
phenotypic proﬁles, through immunologic and molecular
methods, showed a signiﬁcant higher frequency of S. aureus
strains expressing molecules associated with virulence, such
asenterotoxins,adhesins,PVL,bioﬁlmproduction,orMRSA
in children with AD as compared to asymptomatic carriers.
Among these biologic properties, the ability to generate
bioﬁlm or TSST-1 were signiﬁcantly more frequent (P =
0.0003 and P = 0.002, resp.) in patients with a more severe
form of the disease as compared to those with a mild disease
expression according to the criteria described by Haniﬁn and
Rajka[20].Thesefactorsmaythushaveanimportantimpact
on the clinical outcome and disease severity.
6. Conclusions
Our data suggest that the nasal cavity represent a key source
for S. aureus skin colonization and that the familiar environ-
ment may play an important role in S. aureus colonization.Clinical and Developmental Immunology 5
Table 6: Immunological detection of toxin array and drug resistance of S. aureus isolates from patients and their family members.
Source of isolate Localization Enterotoxins TSST-1 Antibiotic resistance
Patient 6 Lesional skin SEC GM, P
Nose SEC P
Patient 6, father Nose SEC P
Patient 6, mother Nose SEC P
Patient 10 Lesional skin SEC P
Patient 10, father Nose SEC P
Patient 15 Lesional skin SEB OX, P, E
Nose SEB P
Healthy skin SEB OX, CM, MUP, RF
Patient 15, mother Nose SEB P, CM,
Patient 16 Lesional skin SEA, TSST-1 P, E, MUP
Nose SEA, TSST-1 P, E, MUP
Healthy skin SEA, TSST-1 P, E, MUP
Patient 16, father Nose SEA, TSST-1 OX, P, E, MUP, MXF,
CM, TEC, TE, FA
Patient 19 Nose P
Patient 19, mother Nose P
Patient 21 Lesional skin FF
Nose Te
Patient 21, father Nose SEA, SED P
Patient 21, mother Nose SEA, SED P
Patient 23 Lesional skin P
Nose P
Patient 23, father Nose P, CM, E
Patient 23, mother Nose P
Patient 25 Lesional skin
Patient 25, mother Nose
Patient 26 Lesional skin P, FF
Nose TSST-1 P
Healthy skin P, FF
Patient 26, father Nose P, FF
Patient 26, mother Nose TSST-1 P, E, CM
Patient 26, brother Nose TSST-1 P, E, CM
Patient 27 Lesional skin SEB P, E, CM
Nose SEB P, E, CM
Patient 27, mother Nose SEB P, E, CM
Patient 27, brother Nose SEB P, E, CM
Patient 28 Lesional skin
Patient 28, father Nose P, MUP
Patient 28, mother Nose TSST-1
Patient 29 Lesional skin TSST-1 P
Patient 29, mother Nose TSST-1 P
Patient 30 Lesional skin TSST-1 P
Nose P
Patient 30, mother Nose TSST-1 P
Patient 31 Nose SEC P, E, CM
Patient 31, mother Nose SEC P, E, CM
Patient 32 Nose
Patient 32, father Nose TSST-1 P
Patient 32, mother Nose TSST-1 P6 Clinical and Developmental Immunology
Table 6: Continued.
Source of isolate Localization Enterotoxins TSST-1 Antibiotic resistance
Patient 33 Nose TSST-1 P
Patient 33, mother Nose TSST-1 P
Patient 38 Lesional skin P
Nose P
Patient 38, father Nose P
Patient 38, sister Nose P
Patient 44 Lesional skin SEC P, E, CM, FF
Nose SEC P, E, CM
Healthy skin SEC P, E, CM
Patient 44, father Nose SEC
Patient 44, mother Nose SEC P, E, CM
Patient 45 Nose TSST-1 P
Patient 45, mother Nose TSST-1 P
Patient 58 Lesional skin P
Nose P
Patient 58, father Nose P
Patient 58, sister Nose P
Abbreviations:P:Benzylpenicillin;OX:Oxacillin;CM:Clindamycin;E:Erythromycin;FF:Fosfomycinandnitrofurantoin;FA:FusidicAcid;GM:Gentamicin;
MXF: Moxiﬂoxacin; MUP: Mupirocin; RF: Rifampicin; TEC: Teicoplanin; TE: Tetracycline.
Therefore, the eradication of these reservoirs might have
a key impact on both the frequency and outcome of AD
[33]. These results may indicate that clinical management of
AD should include a routine testing for S. aureus not only
on skin lesion but also in other important body reservoirs
such as the nasal cavity [31] and emphasizes the need of
performingsusceptibilitytestsforantimicrobialdrugsbefore
initiating the therapy. In addition, routine testing should
include also the family members of AD patients in order to
break the chain of transmission through the establishment of
an appropriate antibacterial therapy.
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